Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 11/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 9/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | CCR2 | P41597 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328118 | 0.90 | ROCK2 (0.48) | PRKCZPRKD2ROCK2ROCK1CCR2 | |
| SCHEMBL29897353 | 0.88 | PRKCZ (0.58) | PRKCZPRKD2ROCK2ROCK1CCR2 | |
| SCHEMBL23301223 | 0.88 | PRKCZ (0.58) | PRKCZPRKD2ROCK2ROCK1CCR2 | |
| SCHEMBL23328161 | 0.85 | PRKCZ (0.55) | PRKCZPRKD2ROCK2ROCK1 | |
| SCHEMBL30175754 | 0.85 | PRKCZ (0.55) | PRKCZPRKD2ROCK2ROCK1 | |
| SCHEMBL25043768 | 0.85 | FGFR1 (0.41) | PRKCZ | |
| SCHEMBL29897378 | 0.78 | PRKCZ (0.59) | PRKCZPRKD2ROCK2ROCK1CCR2 | |
| SCHEMBL23301001 | 0.78 | PRKCZ (0.59) | PRKCZPRKD2ROCK2ROCK1CCR2 | |
| SCHEMBL23328348 | 0.78 | DYRK1A (0.46) | PRKCZ | |
| SCHEMBL23301499 | 0.75 | ABL1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084265-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | PRKCZ 717/4885PRKD2 542/4885ROCK2 359/4885 |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | PRKCZ 875/4885PRKD2 314/4885ROCK2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.